Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial.

@article{Lovell2003LongtermEA,
  title={Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial.},
  author={Daniel J. Lovell and Edward H. Giannini and Andreas Otto Reiff and Olcay Y. Jones and Rayfel Schneider and Judyann C. Olson and Leonard D Stein and Abraham Gedalia and Norman T. Ilowite and Carol A. Wallace and Mary E Lange and Barbara K Finck and Daniel J Burge},
  journal={Arthritis and rheumatism},
  year={2003},
  volume={48 1},
  pages={218-26}
}
OBJECTIVE To evaluate the long-term efficacy and safety of etanercept in children with juvenile rheumatoid arthritis (JRA) participating in an ongoing multicenter, open-label, extended-treatment trial. All patients had been participants in an initial randomized efficacy and safety trial of etanercept. METHODS Etanercept was administered at a dosage of 0.4 mg/kg (maximum 25 mg) subcutaneously twice each week. Safety and efficacy evaluations were performed every 3-4 months. The JRA 30… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 73 extracted citations

Similar Papers

Loading similar papers…